GLP-1 Drugs and Addiction: Could Ozempic Treat Substance Use Disorders?

The connection between GLP-1 drugs and reduced addictive behavior has moved from anecdotal reports to large-scale observational studies and controlled clinical trials:

March 2026: Veterans study. In a study of veterans with substance use disorders, those taking GLP-1 medications had 50% fewer deaths due to substance use compared to those not taking GLP-1 drugs. Published in Science, this is the strongest mortality signal to date.

Clinical trials for alcohol use disorder. Semaglutide trials have shown reduced alcohol craving and consumption in people with AUD. The results are described as "encouraging" by the Endocrine Society, with effect sizes comparable to existing addiction medications.

Observational data. Multiple retrospective analyses show that patients prescribed GLP-1 drugs for diabetes or obesity report reduced consumption of alcohol, nicotine, and other substances. The effect appears consistent across studies and populations.

Mechanistic evidence. The May 2026 Nature study showing central amygdala activation by oral GLP-1 drugs provides a neurobiological explanation for these observations.

The central finding from the 2026 Nature study is that GLP-1 drugs do not just suppress appetite — they modulate the brain’s reward circuitry at a fundamental level.

The central amygdala is a key node in the brain’s reward network. It processes desire and connects to dopamine-producing regions that drive the wanting of pleasurable experiences — whether food, alcohol, drugs, or other rewards. When GLP-1 drugs activate receptors in this region, they reduce dopamine release during reward-seeking behavior.

This explains a pattern that GLP-1 users widely report: not just eating less, but wanting less. Reduced interest in alcohol, food, shopping, gambling, and other compulsive behaviors all point to a shared mechanism — dampened reward signaling.

Critically, this is different from how most existing addiction medications work. Naltrexone blocks opioid receptors. Disulfiram makes alcohol consumption unpleasant. Methadone replaces the opioid. GLP-1 drugs appear to reduce the underlying wanting that drives addictive behavior across substance types.

As of May 2026, more than a dozen clinical trials are testing GLP-1 receptor agonists for addiction:

Alcohol use disorder: Multiple trials of semaglutide for AUD, including at least one funded by a major pharmaceutical company. Early results show reduced craving and consumption.

Nicotine dependence: Trials testing whether GLP-1 drugs reduce cigarettes per day and prevent the weight gain that commonly follows smoking cessation — a dual benefit that could significantly improve quit rates.

Opioid use disorder: Observational data prompted trials, though these are in earlier stages. The 50% mortality reduction in veterans provides a strong rationale.

Eli Lilly trial: The manufacturer of tirzepatide is conducting its own addiction-related trial, expected to report results later in 2026.

If these trials succeed, pharmaceutical companies could seek FDA approval for addiction as a new indication for GLP-1 drugs. Given that substance use disorders affect approximately 48 million Americans and existing treatments have limited efficacy, the market potential is enormous.

Despite the promising signals, several important caveats apply:

Observational ≠ causal. The veterans study and retrospective analyses show associations, not causation. People prescribed GLP-1 drugs may differ from non-users in ways that independently affect substance use outcomes. Randomized trials are needed to establish causation.

The brain study was in mice. The central amygdala mechanism was demonstrated in animal models. Human neuroimaging confirmation is needed.

Off-label prescribing is limited. The FDA has not approved GLP-1 drugs for addiction. Physicians can prescribe off-label, but insurance typically will not cover GLP-1 drugs prescribed solely for substance use disorders. Most current off-label use occurs in patients who also qualify for approved indications (diabetes or obesity).

Side effects matter. GLP-1 drugs cause significant GI side effects (nausea, vomiting, diarrhea) in a substantial proportion of users. For addiction patients, treatment adherence with a medication that causes nausea could be challenging.

The cost barrier. Even with recent price cuts, GLP-1 drugs remain expensive. Broad use for addiction treatment would require either FDA approval (enabling insurance coverage) or significant further price reductions.